TCM Biotech International Corp. (TPEX:4169)

Market Cap	3.04B
Revenue (ttm)	666.53M
Net Income (ttm)	21.01M
Shares Out	59.05M
EPS (ttm)	0.36
PE Ratio	142.78
Forward PE	25.70
Dividend	0.29 (0.56%)
Ex-Dividend Date	n/a

Volume	12,012
Average Volume	40,207
Open	51.00
Previous Close	51.30
Day's Range	49.90 - 51.40
52-Week Range	43.65 - 63.60
Beta	-0.20
RSI	44.59
Earnings Date	Apr 18, 2025

About TCM Biotech International

TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for the prevention and treatment of liver diseases. The company’s products include osteoarthritis treatment products, osteoporosis treatment preparations, iron supplement, urinary system treatment products, expectorants/mucolytic agents, anti-hypertensive preparations, and anti-diabetic preparations, anti-adhesion systems, pellefeel wound care systems, Philips non-invasive ventilators, and others, as well as medical devices and functional foods....

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1998
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4169

Financial Performance

In 2024, TCM Biotech International's revenue was 666.53 million, a decrease of -31.26% compared to the previous year's 969.62 million. Earnings were 21.01 million, an increase of 13.12%.